The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Subscribe To Our Newsletter & Stay Updated
